key: cord-335516-om7w8y0t authors: Larsen, Julie Brogaard; Pasalic, Leonardo; Hvas, Anne-Mette title: Platelets in Coronavirus Disease 2019 date: 2020-04-30 journal: Semin Thromb Hemost DOI: 10.1055/s-0040-1710006 sha: doc_id: 335516 cord_uid: om7w8y0t nan Thrombocytopenia is reported in 5 to 40% 4, 6, 8, 9 of COVID-19 patients and appears to be associated with more severe disease. A meta-analysis by Lippi et al, 10 including nine studies with more than 1,700 COVID-19 patients in total, reported a significant association between thrombocytopenia at admission and severe disease. Platelet counts were significantly lower in severely ill patients (weighted mean difference: -31.5 Â 10 9 /L) and were associated with increased mortality in a subgroup analysis. This is supported by additional studies [11] [12] [13] 12 It should be noted that the study by Wang et al is still in the process of completing peer review. Finally, a study by Tang et al including 449 patients found platelet count to be negatively correlated with 28-day mortality in a multivariate analysis. 13 However, the majority of even severely ill COVID-19 patients exhibit only mild thrombocytopenia. One case series (n ¼ 62) reported that only 5% of patients had platelets counts < 100 Â 10 9 /L, 14 and in 69 patients from Singapore, no patients had platelet counts < 100 Â 10 9 /L at admission. 9 In studies reporting on platelet count in COVID-19, mean platelet counts ranged from $ 160 to 215 Â 10 9 /L in COVID-19 patients in general 4,6-8,11,12,15-18 to 120 to 200 Â 10 9 /L in severely ill patients. 4, 6, 7, 11, 12, [15] [16] [17] 19, 20 Tang et al reported on the association between coagulopathy and mortality in 183 COVID-19 patients. 5 Of the 21 patients who did not survive, 12 (57%) had platelet counts < 100 Â 10 9 /L. Based on these data, it appears that while mild thrombocytopenia is a common finding in COVID-19 patients, a platelet count of < 100 Â 10 9 /L seems rare and should be interpreted as an indicator of present or developing coagulopathy. This could help identify patients who could benefit from thromboprophylaxis. 13 Interestingly, Qu et al demonstrated an association between high platelet counts and poor prognosis. 21 The authors found that severely ill COVID-19 patients exhibited higher peak platelet counts than their nonseverely ill peers during hospital admission and that the platelet-to-lymphocyte ratio during platelet peak was markedly higher in severely ill patients. However, the study included 30 patients in total, with only 3 with severe disease. Thus, these findings should be replicated in other cohorts before the platelet-to-lymphocyte ratio can be better investigated as a prognostic factor. Furthermore, low lymphocyte counts have consistently been found associated with worse prognosis, 4,6 and this may be the explanation for the findings described by Qu et al, more than the high platelet counts per se. Platelets are known to interact directly with several different types of virus through surface integrins, P-selectin, and toll-like receptors, as recently reviewed in detail in this journal by Page and Pretorius. 22 Regarding interactions between SARS-CoV-2 and platelets, however, current knowledge is sparse. Some lessons may be learned from the SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) outbreaks in 2002 to 2003 and 2012, where similar findings have been described of thrombocytopenia, predominantly mild, in 30 to 50% of patients. [23] [24] [25] [26] Mechanisms behind thrombocytopenia in the 2003 SARS-CoV infection have been reviewed by Yang et al. 27 These may include both a direct influence of the virus on hematopoiesis and megakaryocyte maturing, and an increased platelet adhesion and activation and subsequent platelet consumption in the microcirculation of damaged lung tissue. 27 Platelet activation in the pulmonary microcirculation could not only contribute to the procoagulant activity described in COVID-19 patients but also aggravate damage to the lung parenchyma and contribute to the respiratory distress and frequent need for mechanical ventilation, which is a hallmark of severe COVID-19. Finally, hyperinflammation appears to be a prominent feature of severe COVID-19, as increased serum levels of ferritin, interleukin-6, and other proinflammatory cytokines have been reported and are linked to worse prognosis in 7, 28, 29 This could also contribute to platelet activation in COVID-19. 30 These data open interesting perspectives for the role of platelet activation and for possible benefits of antiplatelet agents in COVID-19. However, these questions should be explored in future research since, to the best of our knowledge, no study has yet reported on platelet activation in COVID-19 patients. To conclude, mild thrombocytopenia is a common finding in COVID-19, and thrombocytopenia is linked with more severe disease and mortality. Platelet counts < 100 Â 10 9 /L should lead the clinician to suspect the development of complications in the COVID-19 patient, for example, DIC. Our current knowledge of other human coronaviruses suggests that ongoing platelet activation in pulmonary and other tissues could be present in COVID-19 and could hence contribute to increased procoagulant activity observed in COVID-19. However, to the best of our knowledge, platelet function testing has not been performed in COVID-19 patients so far. This is a focal point for future research to increase our understanding of the pathophysiology of COVID-19 and explore possible treatment targets. Dr. Hvas reports grants from CSL Behring and other fees from CSL Behring, Boehringer Ingelheim, and Bayer, outside the submitted work. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Hematologic parameters in patients with COVID-19 infection Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Clinical course and outcome of novel coronavirus COVID-19 infection in 107 patients discharged from the Wuhan hospital Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore Seminars in Thrombosis & Hemostasis Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study Characteristics and outcomes of 21 critically ill patients With COVID-19 in Washington state Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China COVID-19 in critically ill patients in the Seattle region -case series A champion of host defense: a generic largescale cause for platelet dysfunction and depletion in infection Princess Margaret Hospital SARS Study Group. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study Thrombocytopenia in patients with severe acute respiratory syndrome (review) Dysregulation of immune response in patients with COVID-19 in Wuhan, China Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 Platelet activation induced by interleukin-6: evidence for a mechanism involving arachidonic acid metabolism Seminars in Thrombosis & Hemostasis Platelets in COVID-19 Larsen et al. 825